Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2009
|
| gptkbp:ATCCode |
N03AG04
|
| gptkbp:blackBoxWarning |
permanent vision loss
|
| gptkbp:CASNumber |
60643-86-9
|
| gptkbp:chemicalFormula |
C6H11NO2
|
| gptkbp:eliminationHalfLife |
5-8 hours
|
| gptkbp:genericName |
gptkb:vigabatrin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sabril
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:mechanismOfAction |
GABA transaminase inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
confusion
fatigue weight gain drowsiness visual field loss |
| gptkbp:synonym |
gptkb:vigabatrin
|
| gptkbp:usedFor |
epilepsy
infantile spasms refractory complex partial seizures |
| gptkbp:bfsParent |
gptkb:vigabatrin
|
| gptkbp:bfsLayer |
6
|